Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Glioblastoma 49Breast Neoplasms 49Prostatic Neoplasms 47Carcinoma, Non-Small-Cell Lung 47Squamous Cell Carcinoma of Head and Neck 37Lung Neoplasms 29Head and Neck Neoplasms 26Glioma 22Rectal Neoplasms 21Sarcoma 20Neoplasms 20Brain Neoplasms 20Oropharyngeal Neoplasms 16Esophageal Neoplasms 15Uterine Cervical Neoplasms 14Neoplasm Metastasis 14Astrocytoma 13Triple Negative Breast Neoplasms 12Esophageal Squamous Cell Carcinoma 12Carcinoma, Hepatocellular 12Pancreatic Neoplasms 11Melanoma 11Gliosarcoma 10Colorectal Neoplasms 10Stomach Neoplasms 9Small Cell Lung Carcinoma 9Lymphoma 9Hodgkin Disease 9Carcinoma, Squamous Cell 9Urinary Bladder Neoplasms 8

Interventions

Radiotherapy 3Radiation 3Magnetic Resonance Spectroscopy 3relugolix 2luprolide acetate gel depot 2enzalutamide 2bicalutamide 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2Specimen Handling 2Radiosurgery 2Leuprolide 2Goserelin 2Biopsy 2radium Ra 223 dichloride 1niraparib 1histrelin 1gallium 68 PSMA-11 1darolutamide 1abiraterone 1X-Rays 1Triptorelin Pamoate 1Surgical Procedures, Operative 1Salicylic Acid 1Radium-223 1Radiotherapy, Image-Guided 1Radiation Dose Hypofractionation 1Proton Therapy 1Prednisone 1Lymph Node Excision 1Glutamate Carboxypeptidase II 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Prostate Adenocarcinoma × Radiotherapy × 1 year × Clear all
NCT03274687 2026-05-20

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

NRG Oncology

Phase 3 Completed
296 enrolled 29 charts
Genitourinary

Prostate Adenocarcinoma

NCT05050084 2026-05-04

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NRG Oncology

Phase 3 Active not recruiting
2,050 enrolled
Genitourinary

Prostate Adenocarcinoma

NCT04175431 2025-12-18

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

University of Washington

Phase 2 Recruiting
100 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡